Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+HER2-breast cancer :KEYNOTE-756

Fatima Cardoso, Joyce O'Shaughnessy, Heather McArthur,Peter Schmid, Javier Cortes, Nadia Harheck,Melinda L. Telli, David W. Cescon,Peter A. Fasching, Zhimin Shao,Delphine Loirat, Yeon Hee Park, Manuel Gonzalez Fernandez,Gabor Rubovszky, Seock-Ah Im,Rina Hui, Toshimi Takano,Fabrice Andre, Hiroyuki Yasojima,Zhenzhen Liu

ANNALS OF SURGICAL ONCOLOGY(2024)

引用 0|浏览14
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要